Tivic Health secures BARDA Techwatch meeting for Entolimod ARS program

Valion Bio, Inc.

Meeting with BARDA's Radiological and Nuclear Medical Countermeasures Program staff to discuss Entolimod for acute radiation syndrome.
Tivic will present clinical data, manufacturing readiness, and BLA preparations; meeting may lead to funding or purchasing.
Entolimod has FDA Fast Track and Orphan Drug designations for ARS.
CEO states this supports strategy for government partnership or acquisition pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.